WX4 Stock Chart & Stats
€45.23
€0.08(0.18%)
At close: 4:00 PM EDT
€45.23
€0.08(0.18%)
Day’s Range― - ―
52-Week Range€33.63 - €46.00
Previous CloseN/A
Volume0.00
Average Volume (3M)148.00
Market Cap
€13.30B
Enterprise Value€19.18K
Total Cash (Recent Filing)€39.04M
Total Debt (Recent Filing)€4.02B
Price to Earnings (P/E)17.5
Beta-0.09
Next Earnings
Oct 29, 2026EPS Estimate
0.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.89
Shares Outstanding303,013,000
10 Day Avg. Volume67
30 Day Avg. Volume148
Financial Highlights & Ratios
PEG Ratio0.77
Price to Book (P/B)2.53
Price to Sales (P/S)10.96
P/FCF Ratio14.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€45.61Price Target Upside0.84% Upside
Rating ConsensusHold
Number of Analyst Covering11
EPS Forecast (FY)1.74
Revenue Forecast (FY)€945.05M
Bulls Say, Bears Say
Bulls Say
Material DeleveragingSustained reduction in leverage improves credit flexibility and lowers refinancing risk for a rate-sensitive REIT. A stronger balance sheet supports dividend coverage, enables accretive redeployment from asset sales, and increases resilience to operator stress over the next 2–6 months.
Revenue And Profitability MomentumConsistent top-line growth and materially higher margins indicate improving core cash flow generation and operating leverage. Durably stronger revenue and profit margins bolster AFFO/FFO support for dividends and provide headroom to fund selective investments over coming quarters.
Liquidity, Active Deployment And RIDEA PipelineLarge disposals and repayments created ~$700M liquidity enabling paydown of revolver and $470M of new investments. A visible, accretive pipeline—including expanded RIDEA structures and U.K. entry—supports durable growth and redeployment into higher-return healthcare real estate.
Bears Say
Sharp FCF DecelerationA marked decline in free cash flow weakens near-term internal funding capacity and reduces margin for error on distributions or reinvestments. Even with healthy absolute cash levels, persistent FCF volatility could constrain redeployment timing and dividend flexibility over the next several quarters.
Unresolved Bankruptcy Exposure (Genesis)Pending resolution of a sizeable borrower bankruptcy creates uncertainty about recoveries and timing of cash receipts. Delays or shortfalls in repayment could pressure liquidity, restrict redeployment plans, and add credit-loss risk to loan/FFO metrics in the medium term.
Operator-specific Coverage And Occupancy PocketsConcentrated operator stress and localized low occupancy require active remediation and may depress contracted rent or increase capex/transition costs. Such pockets can persist, creating uneven cash flows and raising asset-management intensity and risk over the coming quarters.
Omega Healthcare News
WX4 FAQ
What was Omega Healthcare’s price range in the past 12 months?
Omega Healthcare lowest stock price was €33.63 and its highest was €46.00 in the past 12 months.
What is Omega Healthcare’s market cap?
Omega Healthcare’s market cap is €13.30B.
When is Omega Healthcare’s upcoming earnings report date?
Omega Healthcare’s upcoming earnings report date is Oct 29, 2026 which is in 87 days.
How were Omega Healthcare’s earnings last quarter?
Omega Healthcare released its earnings results on Jul 29, 2026. The company reported €1.031 earnings per share for the quarter, beating the consensus estimate of €0.441 by €0.59.
Is Omega Healthcare overvalued?
According to Wall Street analysts Omega Healthcare’s price is currently Undervalued.
Does Omega Healthcare pay dividends?
Omega Healthcare does not currently pay dividends.
What is Omega Healthcare’s EPS estimate?
Omega Healthcare’s EPS estimate is 0.42.
How many shares outstanding does Omega Healthcare have?
Omega Healthcare has 303,013,000 shares outstanding.
What happened to Omega Healthcare’s price movement after its last earnings report?
Omega Healthcare reported an EPS of €1.031 in its last earnings report, beating expectations of €0.441. Following the earnings report the stock price went down -2.682%.
Which hedge fund is a major shareholder of Omega Healthcare?
Currently, no hedge funds are holding shares in DE:WX4
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Omega Healthcare Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€45.61 (0.84% Upside)
€45.61 (0.84% Upside)
Blogger Sentiment
Bullish
DE:WX4 Sentiment 60%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
41.13%
12-Months-Change
Fundamentals
Return on Equity
5.24%
Trailing 12-Months
Asset Growth
5.45%
Trailing 12-Months
Company Description
Omega Healthcare
Omega Healthcare Investors, Inc. functions as a Real Estate Investment Trust (REIT) primarily focused on the long-term healthcare sector. The company strategically invests in properties providing skilled nursing and assisted living services. A diverse array of healthcare operators manage these assets, predominantly utilizing a triple-net lease framework. Its portfolio is geographically distributed across all regions of the United States and also includes holdings in the United Kingdom.
WX4 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong underlying fundamentals: year-over-year revenue and AFFO growth, significant liquidity and deleveraging, strategic asset sales executed at attractive economics, improved portfolio coverage, a robust investment pipeline (including first U.K. RIDEA), and a modestly tightened upward guidance. Near-term results are being muted by intentional strategic asset sales and loan repayments, and a small number of operator-specific issues (Genesis bankruptcy, Ciena transitions, localized occupancy gaps) and regulatory risks create some near-term uncertainty. Overall, management projects these actions will strengthen credit support and enable accretive redeployment in H2 2026 and 2027.View all DE:WX4 earnings summariesWX4 Stock 12 Month Forecast
Average Price Target
€45.61
▲(0.84% Upside)
Technical Analysis
Healthpeak Properties
―
Sabra Healthcare REIT
―
Healthcare Realty Trust
―
CareTrust REIT
―
American Healthcare REIT, Inc.
―